Loading stock data…
Polaryx Therapeutics (PLYX)
$2.53+0.13 (+5.42%)
Market ClosedLast close Jun 29
Polaryx Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of disease-modifying therapies for rare and pediatric lysosomal storage disorders in the United States.
Historical Price
Price (Candle)
Synthesizing Whystock Narrative...
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$1.96M↓ | -$911,000↑ | -$974,000↓ | -$884,000↑ | -$5.05M |
| Net Income | -$2.54M↓ | -$1.50M↓ | -$1.43M↓ | -$1.01M↑ | -$5.05M |
Peer Comparison
JNJUNHPFE
Fundamentals
Polaryx Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of disease-modifying therapies for rare and pediatric lysosomal storage disorders in the United States. Its pipeline incl...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$112.65M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-260.33%
Volume
Today's trading volume
321,847
